Congenital Heart Disease and Pulmonary Hypertension

Revista Portuguesa de Cardiologia

Volumn 23, Issue 2, 2004, Pages 273-281

  Beghetti, Maurice ^a,b  

^a University Hospital   (Switzerland)

^b Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Cardiac surgery; Congenital heart disease; Pathophysiology; Pulmonary hipertension

Indexed keywords

ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOPULMONARY BYPASS; CONGENITAL HEART DISEASE; HEART LUNG TRANSPLANTATION; HEART SURGERY; HUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; REPERFUSION INJURY; SURGICAL RISK;

CHILD; EISENMENGER COMPLEX; HEART DEFECTS, CONGENITAL; HEART FAILURE, CONGESTIVE; HEART-LUNG TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE;

EID: 1942538588     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997;811:60-7.
2. Rubanyi GM. The role of the endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22:S1-S14.
3. Verrier ED, Boyle EM. Endothelial cell injury in cardio-vascular surgery. Ann Thorac Surg 1996;62:915-22.
4. Scott-Burden T, Vanhoutte PM. The endothelium asa regulator of vascular smooth muscle proliferation. Circulation 1993;87:V-51-V-55.
5. Luscher TF. The endothelium. Target and promoter of hypertension. Hypertension 1990;15:482-5.
6. Katz SD. The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Progr Cardiovasc Dis 1995;38:23-50.
7. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. Circulation 1958;28:533-47.
8. Wagenvoort C. Vasoconstriction and medial hypertrophy in pulmonary hypertension. Circulation 1960;22:535-46.
9. Hoffman JIE, Rudolph Am, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981;64:873-7.
10. Haworth SG. Development of the normal and hypertensive pulmonary vasculature. Exp Physiol 1995;80:843-53.
11. Rabinovitch M. Pulmonary hypertension: Pathophysiology as a basis for clinical decision making. J Heart Lung Transplant 1999;11:1041-53.
12. Botney MD. Role of hemodynamics in pulmonary vascular remodeling. Am J Respir Crit Care Med 1999;159:361-4.
13. Vitvitsky EV, Griffin JP, Collins MH, Spray TL, Gaynor WJ. Increased pulmonary blood flow produces endothelial cell dysfunction in neonatal swine. Ann Thorac Surg 1998; 66:1372-7.
14. Black SM, Fineman JR, Steinhorn RH, Bristow J, Soifer SJ. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol 1998;275:H1643-H1651.
15. Reddy MV, Wong J, Liddicoat JR, Johengen M, Chang R, Fineman JR. Altered endothelium-dependent response in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol 1996;271:H562-H570.
16. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 1995;47:87-131.
17. Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996;93:266-71.
18. Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A, Selwyn AP. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998;82:609-14.
19. Celermajer DS, Dollery C, Burch M, Deanfield JE. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 1994;89:2041-4.
20. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium dependent pulmonary artery relaxation in children with congenital heart disease and abnormal hemodynamics. Circulation 1993;87:440-6.
21. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97.
22. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endogenous endothelin-1 in the lung of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
23. Wong J, Reddy VM, Hendricks-Munoz K, Liddicoat JR, Gerrets R, Fineman JR. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol 1995;269:H1965-H1972.
24. Black SM, Bekker J, Johengen M, Soifer SJ, Parry AJ, Fineman JR. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 2000;47:97-106.
25. Black SM, Bekker J, Ovadia B, et al. Endothelin B mediated pulmonary vasoconstriction in 8 week-old lambs with increased pulmonary blood flow. Pediatr Res 2001;49:30A.
26. Adatia I, Haworth SG. Circulating endothelin in children with congenital heart disease. Br Heart J 1993;69:233-6.
27. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Endothelin-1 in children with pulmonary hypertension. Am Rev Respir Dis 1993;148:519-22.
28. Cacoub P, Drent P, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993;71:448-50.
29. Komai H, Adatia I, Elliot MJ, DeLeval MR, Haworth SG. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993; 106:473-8.
30. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Circulation 1991;84:2280-5.
31. Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth S. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88:2117-22.
32. Hall SM, Haworth SG. Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodeling. J Pathol 1992;166:183-193.
33. Iverson RE, Lind LE, Kegel S. The diagnosis of progressive pulmonary vascular disease in children with ventricular septal defects. J Pediatr 1966;68:594-600.
34. Newfeld EA, Sher M, Paul MH. Pulmonary vascular disease in atrioventricular canal defect. Am J Cardiol 1977; 39:721-6.
35. Newfeld EA, Paul MH, Muster AJ, Idriss FS. Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients. Am J Cardiol 1974;34:75-82.
36. Hanley FL, Heinemann MK, Jonas RA, et al. Repair of truncus arteriosus in the neonate. J Thorac Cardiovasc Surg 1993;105:1047-56.
37. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-22.
38. Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984;69:655-67.
39. Epting CL, Wolfe RR, Abman SH, Deutsch GH, Ivy D. Reversal of pulmonary hypertension associated with plexiform lesions in congenital heart disease: a case report. Pediatr Cardiol 2002;23:182-5.
40. Wilson NJ, Seear MD, Taylor GP, Leblanc JG, Sandor GS. The clinical value and risks of lung biopsy in children with congenital heart disease. J Thorac Cardiovasc Surg 1990;99:460-8.
41. Rabinovitch M, Keane JF, Fellows KE, Castaneda AR, Reid L. Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects. Circulation 1981;63:152-64.
42. Ivy DD, Neish SR, Knudson OA, et al. Intravascular ultrasonic characteristics and vasoreactivity of the pulmonary vasculature in children with pulmonary hypertension. Am J Cardiol 1998;81:740-8.
43. Berger RMF, Cromme-Dijkhuis AH, Vanvliet AM, Hess J. Evaluation of the pulmonary vasculature and dynamics with intravascular ultrasound imaging in children and infants. Pediatr Res 1995;38:36-41.
44. Marshall HW, Swan HJC, Burchell HB, Wood EH. Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 1961;23:241-52.
45. Lock JE, Einzig S, Bass JL, Moller JH. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol 1982;3:41-6.
46. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 1993;70:461-8.
47. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-53.
48. Winberg P, Lundell BPW, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994; 71:282-6.
49. Day RW, Lynch JM, Shaddy RE, Osmond GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1995;75:196-8.
50. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996;77:532-5.
51. Atz AM, Adatia I, Lock JE, Weesel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999;33:813-9.
52. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Vasodilator capacity and cellular mechanisms. Circulation 2001;103:544-8.
53. Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 1995;25:1652-64.
54. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprussiate is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48-54.
55. Boyle EM, Pohlman TH, Cornejo CJ, Verrier ED. Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion. Ann Thorac Surg 1996;62:1868-75.
56. Allison RC, Kyle J, Adkins WK, Prasad VR, McCord JM, Taylor AE. Effect of ischemia reperfusion or hypoxia on lung vascular permeability and resistance. J Appl Physiol 1990;69:597-563.
57. Del Nido PJ, Williams WG, Villamater J, Benson LN, Bohn D, Trusler GA. Changes in pericardial surfaces pressure during pulmonary hypertensive crisis after cardiac surgery. Circulation 1987;76:93-6.
58. Tumer-Gomes SO, Andrew M, Coles J, Trusler GA, Williams WG, Rabinovitch M. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992;103:87-97.
59. Serraf A, Sellak H, Hervé P, et al. Vascular endothelium viability and function after cardiopulmonary bypass in neonatal piglets. Am J Respir Crit Care Med 1999;159:544-551.
60. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88(part 1):2128-38.
61. Nyhan D, Redmond J, Gilinov A, Nishiwaki K, Murray P. Prolonged pulmonary vascular hyperreactivity in conscious dogs after cardiopulmonary bypass. J Appl Physiol 1994; 77:1584-90.
62. Morita K, Ihnken K, Buckberg GD, Sherman MP, Ignarro LJ. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann Thorac Surg 1996;61:1775-80.
63. Engelman DT, Watanabe M, Engelman RM, et al. Constitutive nitric oxide release is impaired after ischemia and reperfusion. J Thorac Cardiovasc Surg 1995;110:1047-53.
64. Beghetti M, Silkoff PE, Caramori M, Holtby HM, Slutsky AS, Adatia I. Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg 1998;66:532-4.
65. Rubanyi GM, Ho EH, Cantor HE, Lumma WC, Botelho LHP. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leucocytes. Biochem Biophys Res Comm 1991;181:1392-7.
66. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
67. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
68. Barbotin-Larrieu F, Mazmanian M, Baudet B, et al. Prevention of ischemia-reperfusion injury by inhaled nitric oxide in neonatal piglets. J Appl Physiol 1996;80:782-8.
69. Lefer AM. Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy. Ann Thorac Surg 1995;60:847-51.
70. Engelman DT, Watanabe M, Maulik N, et al. L-arginine reduces endothelial inflammation and myocardial stunning during ischemia-reperfusion. Ann Thorac Surg 1995; 60:1275-81.
71. Schulze-Neick I, Penny DJ, Rigby ML, et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation 1999; 100:749-55.
72. Lindberg L, Sjoberg T, Ingemansson R, Steen S. Inhalation of nitric oxide after lung transplantation. Ann Thorac Surg 1996;61:956-62.
73. Lindberg L, Kimblad PO, Sjoberg T, Ingemansson R, Steen S. Inhaled nitric oxide reveals and attenuates endothelial dysfunction after lung transplantation. Ann Thorac Surg 1996;62:1639-43.
74. Carteaux JP, Roux S, Siaghy M, et al. Acute pulmonary hypertension after cardiopulmonary bypass in pigs: the role of endogenous endothelin. Eur J Cardiothorac Surg 1999; 15:346-52.
75. Reddy MV, Hendricks-Munoz KD, Rajasinghe HA, Petrossian E, Hanley FL, Fineman JR. Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow: a role for endothelin 1. Circulation 1997; 95:1054-61.
76. Petrossian E, Parry AJ, McMullan DM, et al. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance following cardiopulmonary bypass in lambs with increased pulmonary blood flow. J Thorac Cardiovasc Surg 1999;117:314-23.
77. Schulze-Neick I, Li J, Penny DJ, Redington AN. Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg 2001;121:1033-9.
78. Wheller J, George BL, Mulder DG, Jarmakani JM. Diagnosis and management of postoperative pulmonary hypertensive crisis. Circulation 1979:1640-4.
79. Hickey PR, Hansen DD, Wessel DI, Lang P, Jonas RA, Elixson EM. Blunting of stress response in the pulmonary circulation of infants with fentanyl. Anesth Analg 1985; 64:1137-42.
80. Morris K, Beghetti M, Petros A, Mannion A, Adatia I, Bohn D. Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease. Crit Care Med 2000;28:2974-8.
81. Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation 1981;63:87-95.
82. Bhorade S, Christenson J, O'Connor M, Lavoie A, Pohlmann A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart failure. Am J Resp Crit Care Med 1999;159:571-9.
83. Schulze-Neick I, Bultmann M, Werner H, et al. Right ventricular function in patients treated with inhaled nitric oxide after cardiac surgery for congenital heart disease in newborns and children. Am J Cardiol 1997;80:360-3.
84. Journois D, Pouard P, Mauriat P, Malhère T, Vouhé P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994;107:1129-35.
85. Miller OI, Celermajer DS, Deanfield DE, Macrae DJ. Very low dose inhaled nitric oxide: A selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994;108:487-94.
86. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995;73:65-8.
87. Atz AM, Adatia I, Jonas RA, Wessel DL. Inhaled nitric oxide in children with pulmonary hypertension and congenital mitral stenosis. Am J Cardiol 1996;77:316-319.
88. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996;62:1759-64.
89. Goldman AP, Delius RE, Deanfield JE, et al. Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation. Circulation 1996;94:44-8.
90. Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-8.
91. Atz A, Wessel DL. Inhaled nitric oxide in the neonate with cardiac disease. Sem Perinatol 1997;21:441-55.
92. Hare JM, Sherman SK, Body SC, Graydon E, Colucci WS, Cooper GS. Influence of nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 1997;95:2250-3.
93. Eisenmenger V. Die angeborene defecte der kammers-heidewand des herzen. Z Klin Med Suppl 1897;132:1.
94. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958; 2:701-12.
95. Dinh-Xuan At, Higenbottam TW, Clelland C, Pepke-Zakba J, Cremona G, Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1989;99:9-10.
96. Niwa K, Perloff JK, Kaplan S. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999;34:223-32.
97. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745-55.
98. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999;84:677-81.
99. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65.
100. O'Blenes SB, Fischer S, McIntyre B, Keshavjee S, Rabinovitch M. Hemodynamic unloading leads to regression of pulmonary vascular disease. J Thorac Cardiovasc Surg 2001; 121:279-89.